UiPath (NYSE:PATH) Price Target Lowered to $25.00 at Scotiabank

UiPath (NYSE:PATHGet Free Report) had its target price cut by analysts at Scotiabank from $30.00 to $25.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “sector perform” rating on the healthcare company’s stock. Scotiabank’s target price indicates a potential upside of 35.14% from the stock’s current price.

A number of other equities research analysts have also weighed in on PATH. KeyCorp assumed coverage on UiPath in a report on Monday, April 8th. They issued an “overweight” rating and a $27.00 price objective on the stock. Mizuho lifted their price target on shares of UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. JPMorgan Chase & Co. upgraded shares of UiPath from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $22.00 to $28.00 in a research report on Thursday, March 14th. Barclays lifted their price target on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a research report on Friday, March 15th. Finally, Canaccord Genuity Group lifted their price target on shares of UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, UiPath presently has an average rating of “Moderate Buy” and an average target price of $27.12.

Read Our Latest Stock Report on PATH

UiPath Trading Down 1.3 %

Shares of NYSE PATH traded down $0.25 during midday trading on Wednesday, reaching $18.50. 2,396,680 shares of the company were exchanged, compared to its average volume of 7,970,250. UiPath has a 1 year low of $14.12 and a 1 year high of $27.87. The stock has a fifty day simple moving average of $20.46 and a 200 day simple moving average of $22.16. The stock has a market cap of $10.53 billion, a P/E ratio of -107.99 and a beta of 1.01.

UiPath (NYSE:PATHGet Free Report) last announced its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. As a group, analysts forecast that UiPath will post -0.04 earnings per share for the current year.

Insider Activity

In other news, CFO Ashim Gupta sold 16,000 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the completion of the sale, the chief financial officer now directly owns 87,505 shares of the company’s stock, valued at approximately $1,998,614.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 96,000 shares of company stock valued at $2,023,440 in the last ninety days. Company insiders own 22.37% of the company’s stock.

Institutional Trading of UiPath

Institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new stake in UiPath during the 4th quarter worth $165,749,000. Vanguard Group Inc. raised its stake in shares of UiPath by 7.6% in the 3rd quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock valued at $645,916,000 after purchasing an additional 2,673,718 shares in the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of UiPath in the 4th quarter valued at about $48,267,000. Glenmede Trust Co. NA raised its stake in shares of UiPath by 3,273.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company’s stock valued at $26,777,000 after purchasing an additional 1,518,592 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in shares of UiPath in the 4th quarter valued at about $15,543,000. 62.50% of the stock is owned by hedge funds and other institutional investors.

About UiPath

(Get Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Articles

Analyst Recommendations for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.